This review article presents an overview of ophthalmic viscoelastic devices (OVDs) and their application in difficult cases in ophthalmology |
OVDs in cataract surgery protect ocular structures from mechanical trauma, divide tissue, create space, resolve adhesions, act as a wetting agent, or as an instrument to facilitate the surgical procedure |
Good knowledge of all OVD types is mandatory for ophthalmic surgeons to achieve the best results |
Introduction
Types of OVD
Classification of OVDs
-
Viscosity: it describes the flow resistance of OVD. Viscosity changes with different flow rates. The faster an OVD flows, the more the viscosity decreases. This is measured in the ease of injection of the material and is crucial for the mobilizing effects of OVDs during surgery. It is important to note that the viscosity of an OVD is higher when the molecular weight at low shear rate increases [17].
-
Viscoelasticity: it describes the elastic component of the OVD. Therefore, it represents the ability to return to its original shape after being subjected to an external force.
-
Pseudoplasticity: it is the property of OVDs to change from a highly viscous state at rest to an aqueous state at higher shear rates.
-
Cohesive OVDs: they are high-viscosity materials with intramolecular adhesion and entanglement that are particularly useful to create and maintain space in the anterior chamber for a long time [18‐22]. Cohesive OVDs form as a mass and they are easier to be removed as a kind of bolus at the end of the surgical procedure [23].
-
Dispersive OVDs: they are low-viscosity materials with good adherence properties to intraocular structures and instruments, providing special protection to the corneal endothelium during phacoemulsification [16, 18‐22, 24, 25]. However, they are more fragile as a result of their short molecular chains and consequently are more difficult to be remove after finishing surgery [16, 26]. This may result in postoperative OVD residues in the anterior chamber, which can lead to an increase of intraocular pressure (IOP) [27].
Cohesive | Dispersive |
---|---|
High viscosity | Lower viscosity |
High molecular weight | Low molecular weight |
Long chain molecules | Short chain molecules |
More solid | More liquid |
Act like a gel | Adhesive and protective effect |
High surface tension and high degree of pseudoplasticity | Low pseudoplasticity and surface tension |
Adhere to themselves through intramolecular bonds | Adhere to external surfaces like tissues and instruments, lubricate injector cartridges/intraocular lenses |
Create space | High coating ability |
Induce and sustain pressure | Better ability to divide rooms and compartments/partition spaces |
Easier to remove | Complete removal complex/residues/IOP |
Cohesive OVDs
OVD type | OVD name | Composition | Manufacturer |
---|---|---|---|
Cohesive OVDs | Healon | 1% NaHa | Johnson & Johnson Vision, Santa Ana, California |
Healon GV | 1.4% NaHa | ||
Pe-Ha-Luron®F | 1.0/1.4/1.6/1.8/3.0% NaHa | Albomed GmbH, Schwarzenbruck, Germany | |
Pe-Ha-Blue® PLUS | 1.7% NaHA Trypan blue (0.020 mg/ml) | ||
Amvisc | 1.2% NaHa | Bausch & Lomb, Rochester, NY | |
Amvisc Plus | 1.6% NaHa | ||
Z-Hyalin | 1.0% NaHa | Carl Zeiss Meditec AG, Jena, Germany | |
Provisc | 1% NaHa | Alcon, Fort Worth, TX | |
Dispersive OVDs | Viscoat | 4% Sodium chondroitin sulfate, 3% NaHa | Alcon Laboratories, Inc., Fort Worth, Texas |
Healon D | 1% NaHa | Johnson & Johnson Vision, Santa Ana, California | |
OcuCoat | 2% HPMC | Bausch & Lomb, Rochester, NY | |
Pe-Ha-Visco® | 2% HPMC | Albomed GmbH, Schwarzenbruck, Germany | |
Pe-Ha-Visco® PLUS | 2.4% HPMC | Albomed GmbH, Schwarzenbruck, Germany | |
Viscoadaptive OVDs | Healon 5 | 2.3% NaHa | Johnson & Johnson Vision, Santa Ana, California |
Micro Visc Phaco | 2.5% NaHa | Bohus Biotech | |
Combination agents | DiscoVisc | 1.7 NaHA 4% Chondroitin sulfate | Alcon Laboratories, Inc., Fort Worth, Texas |
CombVisc | 1.5/3.0% NaHA | Carl Zeiss Meditec AG, Jena, Germany | |
Amvisc Plus | 1.6% NaHa | Bausch & Lomb, Rochester, NY | |
OVD with lidocaine | VisThesia | 1.0% Lidocaine hydrochloride | Carl Zeiss Meditec AG, Jena, Germany |
OVD with trypan blue | Pe-Ha-Blue® Plus | 1.7% NaHa 0.020 mg/ml Trypan blue | Albomed GmbH, Schwarzenbruck, Germany |